AlphaCore Capital LLC Purchases 1,276 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

AlphaCore Capital LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 364.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,626 shares of the medical research company's stock after buying an additional 1,276 shares during the period. AlphaCore Capital LLC's holdings in Thermo Fisher Scientific were worth $846,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Barrett & Company Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at $28,000. FPC Investment Advisory Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $28,000. Pillar Financial Advisors LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $29,000. Noble Wealth Management PBC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $35,000. Finally, Cassady Schiller Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 89.2% during the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after buying an additional 33 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Scotiabank reduced their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research note on Friday, April 25th. Citigroup dropped their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Finally, Raymond James reissued an "outperform" rating and issued a $667.00 price target (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $607.43.

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock worth $7,305,942 over the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded up $9.59 during trading hours on Tuesday, reaching $403.25. The company had a trading volume of 2,705,443 shares, compared to its average volume of 1,872,755. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The firm has a market cap of $152.22 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 2.99 and a beta of 0.82. The firm's 50 day moving average price is $440.05 and its 200-day moving average price is $503.39.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the firm posted $5.11 EPS. The firm's revenue was up .2% on a year-over-year basis. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.